HIGHLIGHTS
- who: Shweta Pasi from the (UNIVERSITY) have published the Article: Toll/Interleukin-1 Receptor Domain Derived from TcpC (TIR-TcpC) Ameliorates Experimental Autoimmune Arthritis by Down-modulating Th17 Cell Response*, in the Journal: (JOURNAL) of February/19,/2016
- what: Addressing this ambiguity, this study attempts to emphasize the unforeseen role of MyD88 as a valuable therapeutic target in RA.
SUMMARY
Although central to various signaling pathways initiated by IL-1, IL-18, and toll-like receptors, the precise contribution of MyD88 to the development of autoimmunity, particularly rheumatoid arthritis, still needs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.